You are here

Medicinal Sciences

We apply cutting-edge design and process development capabilities to bring best-in-class therapies to patients.

At Pfizer, we are investing in next-generation science and technology to invent tomorrow’s innovative therapies. The breadth and depth of our colleagues’ technical expertise is second to none, and underpins our approach to the discovery and development of medicines and vaccines. The Medicinal Sciences group has a central role in this endeavor, from the conception of an idea all the way through to the delivery of a new therapy to patients.

Pfizer's rich and diverse pipeline includes small-molecule drugs, large-molecule biotherapeutics such as antibodies, as well cell- and gene-based therapies and vaccines. For each of these programs, Pfizer scientists draw on a wealth of state-of-the-art science and technology, spanning many disciplines, with a single aim: to bring a new best-in-class treatment to patients.

Many scientific disciplines play a role
in this process.

At the forefront of this innovation are colleagues from the Medicinal Sciences group, a division of Pfizer’s Worldwide Research and Development organization. Medicinal Sciences is structured so as to reflect our colleagues’ invaluable expertise across a range disciplines, and each key function – Medicine Design, BioMedicine Design, Small Molecule and Biotherapeutics Product and Process Development, and Clinical Trial Supply – has a critical role to play.

biomedicine_design_infographic_logo.png
BioMedicine Design The BMD group is responsible for the design and synthesis of biotherapeutic drug candidates. They are focused on reducing immunogenicity and facilitating fast and cost effective development to improve patient’s quality of life through superior safety, efficacy and convenience.
medicinal_design_infographic_logo.png
Medicine Design Pfizer has a proud tradition of industry leadership in inventing safe and effective small molecule therapies. Our core capabilities in molecule design include structural biology, synthetic, analytical and computational chemistry, chemical biology, and computational science. The group also has strong expertise in drug metabolism and pharmacokinetics.
biologics_and_small_molecules_inforgraphic_logo.png
Small Molecules and Biotherapeutics Product and Process Development Experts within these groups take carefully designed candidate medicines from the laboratory - whether small molecules or biologics – and develop the formulations and manufacturing processes needed to transform them into potential new drugs. Scientists, engineers and technicians develop the formulation needed to support the administration method (e.g., tablet, capsule, injection, inhaler, topical agent) and the manufacturing processes. They are responsible for producing the necessary ingredients and supplies for hundreds of clinical trials conducted around the world, and for performing the scientific analyses related to an agent’s quality, consistency and stability.

What We’re Working On

Hundreds of Medicinal Sciences colleagues begin the multi-faceted process of creating and designing a molecule…

When Pfizer's scientists identify a potential target that may play a role in disease pathology, Medicinal Sciences colleagues begin the multi-faceted process of designing and creating a molecule that can change the function of that target and be used as a safe and effective therapy for patients. Once the molecule itself has been designed, Medicinal Sciences colleagues establish the manufacturing process and produce the supplies that are used in clinical studies. Accomplishing these tasks involves answering many questions – including:

What is the best formulation to deliver this molecule to the target tissue?
How can we make use design and formulation to maximum the therapeutic effect of the molecule?
How can we speed the development process?
How will Pfizer’s manufacturing experts quickly scale the process to ensure adequate levels of the molecule are available for clinical studies?
How do we ensure that subjects get the right therapeutic regimen they are assigned to get during a clinical study regardless of where they are in the world?
Can these same experts scale the process further to create commercial quantities of a drug once it is approved by the relevant regulatory agencies?

Meet Some of Pfizer’s Medicinal Sciences Researchers